Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis

BACKGROUND: Lower gastrointestinal (GI) tract involvement can affect up to 50% of systemic sclerosis (SSc) patients, and may result in malabsorption, pseudo-obstruction, hospitalization, and death. We report our experience with linaclotide, a selective agonist of guanylate cyclase C (GC-C), for SSc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dein, Eric J., Wigley, Fredrick M., McMahan, Zsuzsanna H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051106/
https://www.ncbi.nlm.nih.gov/pubmed/33858329
http://dx.doi.org/10.1186/s12876-021-01738-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051106/
https://www.ncbi.nlm.nih.gov/pubmed/33858329
http://dx.doi.org/10.1186/s12876-021-01738-0

Ejemplares similares